Be part of the knowledge.™

Oncology and Hematology

1890

LikeLikedUnlike

Episodes 211-225 of 265

Accurate Staging and Determining Resectability in NSCLC
MinuteCE®
Accurate Staging and Determining Resectability in NSCLC
- Joshua E. Reuss, MD
  Peer
1.00 program credits
Resolving Practice Barriers to Consolidative Immunotherapy in Stage III NSCLC
MinuteCE®
Resolving Practice Barriers to Consolidative Immunotherapy in Stage III NSCLC
- Jhanelle E. Gray, MD
  Peer
- Joshua E. Reuss, MD
  Peer
1.00 program credits
Selection of BTK Inhibitor Following Frontline Chemoimmunotherapy in Older Patients With Comorbidities
MinuteCE®
Selection of BTK Inhibitor Following Frontline Chemoimmunotherapy in Older Patients With Comorbidities
- Mazyar Shadman, MD, MPH
  Peer
0.50 program credits
Safety and Tolerability of Changing Covalent BTK Inhibitor Treatment in a Patient Intolerant to Ibrutinib or Acalabrutinib
MinuteCE®
Safety and Tolerability of Changing Covalent BTK Inhibitor Treatment in a Patient Intolerant to Ibrutinib or Acalabrutinib
- Mazyar Shadman, MD, MPH
  Peer
0.50 program credits
Initial BTK Inhibitor-Based Treatment Selection in a Treatment-Naive, Symptomatic, Unfit Older Patient With Comorbidities and High-Risk Cytogenetics
MinuteCE®
Initial BTK Inhibitor-Based Treatment Selection in a Treatment-Naive, Symptomatic, Unfit Older Patient With Comorbidities and High-Risk Cytogenetics
- Mazyar Shadman, MD, MPH
  Peer
0.50 program credits
MinuteCE®
Case by Case: Personalized BTK-Based Approach for Managing CLL/SLL
- Mazyar Shadman, MD, MPH
  Peer
0.50 credits 3 episodes
Optimal Sequencing of ADCs in Endocrine Refractory HR+/HER2- Metastatic Breast Cancer
CME/CE
Optimal Sequencing of ADCs in Endocrine Refractory HR+/HER2- Metastatic Breast Cancer
- Javier Cortes, MD, PhD
  Peer
- Komal Jhaveri, MD, FACP
  Peer
0.50 credits
Managing Immune-Related Adverse Events With Immunotherapies
MinuteCE®
Managing Immune-Related Adverse Events With Immunotherapies
- Nabil F. Saba, MD, FACP
  Peer
- Barbara Burtness, MD
  Peer
0.50 program credits
Overcoming Barriers to Equitable Care in HNSCC
MinuteCE®
Overcoming Barriers to Equitable Care in HNSCC
- Nabil F. Saba, MD, FACP
  Peer
- Barbara Burtness, MD
  Peer
0.50 program credits
Current and Emerging Biomarkers of Response to Immunotherapeutic Regimens
MinuteCE®
Current and Emerging Biomarkers of Response to Immunotherapeutic Regimens
- Nabil F. Saba, MD, FACP
  Peer
- Barbara Burtness, MD
  Peer
0.50 program credits
The Role of Immunotherapy in the Treatment of Recurrent or Metastatic HNSCC: The Evidence
MinuteCE®
The Role of Immunotherapy in the Treatment of Recurrent or Metastatic HNSCC: The Evidence
- Nabil F. Saba, MD, FACP
  Peer
- Barbara Burtness, MD
  Peer
0.50 program credits
MinuteCE®
Immune Checkpoint Therapy for Patients With Recurrent or Metastatic HNSCC
- Nabil F. Saba, MD, FACP
  Peer
- Barbara Burtness, MD
  Peer
0.50 credits 5 episodes
Optimizing First-Line Immunotherapy for Recurrent or Metastatic HNSCC
MinuteCE®
Optimizing First-Line Immunotherapy for Recurrent or Metastatic HNSCC
- Nabil F. Saba, MD, FACP
  Peer
- Barbara Burtness, MD
  Peer
0.50 program credits
Improving Outcomes and Addressing Racial Disparities in Patients With HR+/HER2- Early Breast Cancer: A Case-Based Learning Lab
CME/CE
Improving Outcomes and Addressing Racial Disparities in Patients With HR+/HER2- Early Breast Cancer: A Case-Based Learning Lab
- Sara M. Tolaney, MD, MPH
  Peer
0.25 credits
First-Line Treatment of Metastatic Melanoma After Adjuvant Anti-PD-1
MinuteCE®
First-Line Treatment of Metastatic Melanoma After Adjuvant Anti-PD-1
- Allison Betof Warner, MD, PhD
  Peer
0.75 program credits

Program Chapters

Segment Chapters

Playlist:

Recommended